Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Synairgen ( (GB:SNG) ) has shared an announcement.
Synairgen has announced the appointment of Martin Murphy as a Non-Executive Director and Chair of the Remuneration Committee. With over 25 years of experience in life sciences investment and leadership roles, Martin Murphy’s expertise is expected to bolster Synairgen’s strategic direction as it prepares for its Phase 2 INVENT trial. His involvement is particularly significant as the company advances its innovative treatment SNG001, which holds promise for patients with critical respiratory conditions.
More about Synairgen
Synairgen is a UK-based respiratory company that specializes in drug discovery and development, focusing on SNG001, an inhaled interferon beta formulation. The company targets the global need for antiviral therapies for severe viral lung infections, aiming to provide the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs.
YTD Price Performance: -18.52%
Average Trading Volume: 553,778
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £11.02M
Find detailed analytics on SNG stock on TipRanks’ Stock Analysis page.
